Artificial intelligence (AI)

The emergence of artificial intelligence (AI) has proved to be an important development in the field of translational nanomedicine, as it has made possible intelligent and personalized applications for precision oncology. The integration of machine learning (ML), deep learning, nanoinformatics, predictive modeling, and computational methods with nano delivery systems has improved carrier design, formulation optimization, multiscale targeting, and therapy monitoring using AI. This article discusses some of the latest developments in the area of AI-assisted translational nanomedicine. It also highlights the use of AI in tumor identification, patient stratification, theranostics, and the application of AI in brain, liver, breast, and kidney cancers. Moreover, cutting-edge developments in digital twins, federated learning, explainable AI, large language models, and intelligent nanorobotics are described for their capacity to speed up clinical translation. While much has been accomplished, there are issues regarding data standardization, clinical validation, scalable manufacturing, regulatory clearance, and algorithm transparency that need to be addressed.

These rare facial diseases, which include hemifacial microsomia, Parry–Romberg syndrome, Moebius syndrome, Treacher Collins syndrome, Apert syndrome, and Crouzon syndrome, among others, pose considerable difficulties in diagnosis and treatment due to their clinical variability, rare occurrence, and complex genetic etiology. This review highlights the increasing potential of artificial intelligence (AI) and machine learning (ML) technologies in the better diagnosis, phenotyping, genotyping, and clinical management of these rare disorders. In this review, the applications of AI to facial phenotyping, three-dimensional (3D) imaging, radiomics, multimodal learning, and explainable AI have been highlighted. It also points out some latest developments in the field of bioinformatics, genome editing, RNA therapies, patient-derived models, and digital twin technology for precision medicine and translational research. Presently, there is sufficient evidence indicating the benefits of AI in increasing the accuracy in diagnosis, objective craniofacial evaluation, and customized treatment plans, whereas computational therapy is still experimental. However, various barriers such as data limitations, variability in phenotype, bias in the algorithms, external validation, ethical issues, and regulation prevent its widespread adoption in clinical practice. Future studies need to concentrate on multicenter data sharing, multimodal explainable AI, precision genomics, and translational framework to speed up the adoption of AI in rare craniofacial medicine.

Artificial intelligence (AI) and translational nanomedicine are revolutionizing the field of precision oncology through the use of smart nanoparticles, personalization of drug delivery, and evidence-based therapeutic decisions. This review highlights some of the recent developments in AI-driven translational nanomedicine, with special emphasis on multistage targeting approaches and clinical utility in liver, breast, renal, and brain tumors. Machine learning, deep learning, radiomics, multimodal omics, and nanoinformatics are among the areas discussed in this review. Tumor heterogeneity, vascular barrier, immune microenvironment, renal clearance, and blood-brain barrier penetration in organs are considered in order to highlight the necessity for the development of personalized nanomedicine strategies. Despite the advancements that have been made by AI-guided nanomedicine in drug delivery, pharmacokinetics and safety, there are several obstacles that hinder the clinical application of such technology. The above review suggests future strategies which include standardization in nanoinformatics, patient-derived organoids, digital twins, federated learning, adaptive clinical trials based on biomarkers, and explainable AI for accelerating clinical translation. It may be concluded that the combination of AI and translational nanomedicine offers an attractive approach towards the development of safer and effective cancer treatment options.